Pharmacological studies with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14).
A novel steroid, (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-yn-3-one (code name Org OD 14), was found to possess concomitant weak oestrogenic, androgenic and progestational activities. The effects observed in other tests, viz. inhibition of ovulation in rats, prevention of bone loss following ovariectomy in rats and restoration of sex drive in castrated male rats, corresponded to this hormonal profile. Studies of the metabolites of Org OD 14 in rats suggested that these are involved in the complex endocrinological properties displayed by the compound.
D000728:Androgens; D000818:Animals; D004967:Estrogens; D005260:Female; D005837:Genitalia, Male / Q000187:drug effects; D008297:Male; D009652:Norpregnenes / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010024:Osteoporosis / Q000517:prevention & control; D010060:Ovulation / Q000187:drug effects; D011372:Progestins; D011817:Rabbits; D051381:Rats; D012726:Sexual Behavior, Animal / Q000187:drug effects; D014599:Uterus / Q000187:drug effects; D014621:Vagina / Q000187:drug effects
D000728:Androgens; D004967:Estrogens; D009652:Norpregnenes; D011372:Progestins; C027385:tibolone